EP0339071A1 - IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE - Google Patents

IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE

Info

Publication number
EP0339071A1
EP0339071A1 EP88909620A EP88909620A EP0339071A1 EP 0339071 A1 EP0339071 A1 EP 0339071A1 EP 88909620 A EP88909620 A EP 88909620A EP 88909620 A EP88909620 A EP 88909620A EP 0339071 A1 EP0339071 A1 EP 0339071A1
Authority
EP
European Patent Office
Prior art keywords
treatment
compound
formula
pyridine
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88909620A
Other languages
German (de)
English (en)
Inventor
Ingemar Starke
Björn Wallmark
Kalervo Väänänen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassle AB filed Critical Hassle AB
Publication of EP0339071A1 publication Critical patent/EP0339071A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Imidazo(1,2-a)(pyridazines or pyrazines) for treatment of diseases related to bone loss.
  • the present invention is related to a novel method for the treatment of several bone affecting diseases, especially osteoporosis, which are characterized by loss of bone mass.
  • bone formation which is associated with the number and activity of osteoblasts, that is cells associated with the production of bone in the organism
  • bone loss which is associated with the number and activity of osteoclasts, that is cells associated with the absorption and removal of bone
  • osteoporosis can be mentioned, Paget's disease of bone, hyperparathyroidism and related disorders, and several malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia.
  • osteoporosis bone formation as well as bone resorption are disturbed, resulting in decreased bone mass. Osteoporosis predominantly affects the elderly, but also other groups such as postmenopausal women, where an estrogen deficit is believed to be a significant etiological factor, and immobilized patients. At this point it is not possible to clear up the whole picture of the disease mechanism and estimate which is the primary cause of osteoporosis. However, about 25 % of osteoporotic females belong to what is called “rapid bone losers" and at least in those patients the bone resorption rate is probably increased. Landry and Fleisch showed in immobilization induced osteoporosis that bone resorption rate was accelerated, (Landry, M. and Fleisch, H, : The influence of immobilization on bone formation as evaluated the incorporation of tetracyclines. J. Bone Joint Surg. 46B:764, 1964).
  • osteoporosis comprise fractures, especially hip fractures, but also vertebral fractures and fractures of the proximal radius, and complication of such fractures.
  • in Finland it has been estimated that about 10 % of all surgical hospital beds are used for the treatment of osteoporosis related fractures (Luthje, P.: Reisiluunkaulan ja trokantterin murtumapotilaiden hoito ja ennuste seka hiodon kustannukset. Thesis. Helsinki 1983).
  • the present methods for the treatment of osteoporosis include exercise; administration of estrogen, especially for postmenopausal women; and consumption of calcium or calcium containing material such as milk.
  • Calcitonin a hormone associated with calcium metabolism, has also been used in the treatment of osteoporosis. None of these methods of treating osteoporosis results in increase of the bone mass.
  • malignant tumors are known to be associated by hypercalcemia which is due to increased osteoclastic activity. This is a common complication for instance in the case of breast cancer and prostate cancer which are both one of the most common malignant tumors.
  • Hypercalcemia is due to both systemic and local factors.
  • Some malignant cells are known to secrete agents which stimulate bone resorption (Sato, K., Fujii, Y. Kachivehi, T., Kasono, K., Shizume, K.: Production of interleukin 1 alpha (IL-1 ⁇ )-like activity and colony stimulating activity by clonal squanous cell carcinomas derived from patients with hypercalcemia and leucocytosis.
  • IL-1 ⁇ interleukin 1 alpha
  • Pacret's disease (or osteitis deformans) of bone is a disease of unknown etiology where bone resorption and remodelling are increased leading sometimes even to the fractures of affected bone. Bone pain is the main indication of treatment in these patients. In these patients there is highly elevated local osteoclastic bone destruction. The incidence of osteitis deformans is very low in Scandinavian countries. In England it has been estimated to be present in 3-4 % of population on the basis of autopsy studies (Anderson's Textbook of Pathology 1986). It is very rare in patients under 40 years. Calcitonin and diphosphonates are also used in the treatment of Paget's disease.
  • Arylalkoxy-, arylalkylamino- and arylalkylthio-substituted imidazo (1,2-a)pyridines and imidazo (1,2-a)pyrazines are known in the art, e.g. EP-Al-0068378 and EP-A1-0033094, as are methods for using these compound to reduce gastric acid secretion.
  • compounds of the general formula I as well as pharmaceutically acceptable salts thereof are effective as inhibitors of basal and stimulated bone resorption and are useful as medicals for the treatment of diseases related to bone loss and increased bone resorption, such as osteoporosis, Pagefs disease of bone, hyperparathyroidism, both primary and secondary, malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia, immobilization-induced osteoporosis, parodontal diseases and prostetic and implant- related bone losses.
  • diseases related to bone loss and increased bone resorption such as osteoporosis, Pagefs disease of bone, hyperparathyroidism, both primary and secondary, malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia, immobilization-induced osteoporosis, parodontal diseases and prostetic and implant- related bone losses.
  • the compounds to be used according to th e i nventi on are of the fol lowing formul a I :
  • A is a nonaromatic 5- or 6-membered ring containing O or 1 heteroatom selected from nitrogen, sulfur and oxygen;
  • R x , B y , R z and R u are H, R 9 or R 10 ;
  • R 9 represents H, loweralkyl, halogen, OH, CF 3 or loweralkoxy
  • R 10 is -Z-T-Ar wherein Z represents -O-, -NH-, -SO m - or a single bond; T represents a straight- or branched chain loweralkylene group; when Z is a single bond, T also represents an ethenylene or a propenylene group wherein the unsaturated carbon is at the single bond; when Z is -O-, T also represent an allylene group wherein the saturated carbon is at the oxygen;
  • n zero, one or two
  • n zero, one or two
  • R 4 and R 5 each independently represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl, Ar, or, when taken together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered cyclic amino group;
  • R 1 represents Ar, loweralkyl, NR 4 R 5 , B-NR 4 R 5 or Ar-loweralkyl;
  • R 6 represents H, C 1 - to C 12 -alkyl, Ar or Ar-loweralkyl
  • R 7 represents H or loweralkyl
  • R 8 represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl or Ar;
  • salts thereof especially acid addition salts such as hydrochloride and hydrobromide salts,
  • R x is R 9 and R Y is H when G is the group
  • halogen includes fluoro, chloro, bromo and iodo, with fluoro and chloro being preferred;
  • lower when applied to alkyl groups, means straight and branched chain alkyl groups having up to six carbon atoms such as methyl, ethyl, propyl, butyl, t-butyl, isopropyl, neopentyl, dimethylbutyl etc., whereby methyl and ethyl are preferred;
  • pyridyl includes the 2-, 3- and 4-isomers and their halogen- or loweralkyl-substituted analogues;
  • thienyl and “furanyl” include the 2- and 3-isomers and their halogen- and loweralkylsubstituted analogues;
  • imidazolyl included the 2- and 4-isomers and their halogen- and loweralkyl-substituted analogues
  • the loweralkylene group represented by T preferably has 1-6, especially 1-3 carbon atoms as in methylene, ethylene and propylene,
  • Suitable “loweralkenyl” may be the ones having 2 to 6 carbon atoms and may include vinyl, allyl, isopropenyl, 1 (or 2 or 3)-butenyl or 1 (or 2 or 3 or 4)-pentenyl.
  • Suitable “loweralkadienyl” may be the ones having 3 to 6 carbon atoms and may include 1,2-propadienyl, 1,2-butadienyl, 1,3-butadienyl, 2,3-pentadienyl or 1,4-pentadienyl.
  • loweralkenyloxy(lower)alkyl suitable examples may include vinyloxymethyl, allyloxymethyl and 1-allyloxyethyl.
  • loweralkynyloxy(lower)alkyl suitable examples may include ethynyloxymethyl, 2-propynyloxymethyl, 2-(2-propynyloxy)ethyl and 1-(2-butynyloxy)propyl.
  • the invention relates to
  • a preferred group of compounds within the general formula I for use according to the present invention is that wherein G is the group
  • Example 1 The compound 8-benzyloxy-3-cyanomethyl-2-methyl-imidazo- (1,2-a)pyridine (Example 1), 8-benzyloxy-3-hydroxylmethyl- 2-methyl-imidazo(1,2-a)pyridine (Example 2) and Example 3 (mentioned above) were tested. As can be seen from Table 1 the compound was found to significantly inhibit both basal bone resorption and PTH-induced bone resportion.
  • the compounds of the formula I are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration.
  • the pharmaceutical formulation contains a compound of the formula I in combination with a pharmaceutically acceptable carrier.
  • the carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule.
  • These pharmaceutical preparations are a further object of the invention.
  • the amount of active compounds is between 0.1-95 % by weight of the preparation, between 0.2-20 % by weight in preparations for parenteral use and between 1 and 50 % by weight in preparations for oral administration.
  • the typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédé de traitement de maladies relatives à la perte de masse osseuse telles que l'ostéoporose, la maladie osseuse de Paget, l'hyperparathyroïdisme, les néoplasmes malins provoquant l'hypercalcémie, les maladies parodontales et les pertes osseuses relatives à des implants, consistant à administrer à un patient souffrant d'une des maladies précitées, une quantité d'un composé de formule (I), ou un sel pharmaceutiquement acceptable de celui-ci.
EP88909620A 1987-10-30 1988-10-27 IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE Withdrawn EP0339071A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8704248A SE8704248D0 (sv) 1987-10-30 1987-10-30 Medical use
SE8704248 1987-10-30

Publications (1)

Publication Number Publication Date
EP0339071A1 true EP0339071A1 (fr) 1989-11-02

Family

ID=20370069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88909620A Withdrawn EP0339071A1 (fr) 1987-10-30 1988-10-27 IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE

Country Status (9)

Country Link
EP (1) EP0339071A1 (fr)
JP (1) JPH02501929A (fr)
KR (1) KR890701587A (fr)
AU (1) AU2620388A (fr)
DK (1) DK322189A (fr)
HU (1) HU203663B (fr)
IL (1) IL88205A0 (fr)
SE (1) SE8704248D0 (fr)
WO (1) WO1989003833A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890701585A (ko) * 1987-07-16 1989-12-21 헤르베르크 슈키·울리히 볼프 새로운 디아졸
US5081253A (en) * 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
US5464843A (en) * 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
JPH11505524A (ja) * 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
GB9518552D0 (en) * 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
CA2620223A1 (fr) 2005-09-02 2007-03-08 Abbott Laboratories Nouveaux heterocycles a base imidazo
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
EP3004094B1 (fr) 2013-06-04 2017-03-01 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines à substitution 3-aryle et leur utilisation
PE20160201A1 (es) 2013-07-10 2016-05-06 Bayer Pharma AG Bencil-1h-pirazol[3,4-b]piridinas y su uso
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
WO2015140199A1 (fr) 2014-03-21 2015-09-24 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-carboxamides cyano-substitués et leur utilisation
US20170050962A1 (en) * 2014-05-02 2017-02-23 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases
WO2015165930A1 (fr) 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft Énantiomères du n-(2-amino-5-fluor-2-méthylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-méthylimidazo[1,2-a]pyridine-3-carboxamide et de ses dérivés difluorés et trifluorés pour traiter des maladies cardiovasculaires
WO2015165970A1 (fr) * 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine carboxamides substitués par chlore en position 6 et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
CA2969268A1 (fr) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines a substitution heteroaryle et leur utilisation
EP3227286B1 (fr) 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Pyrazolo[1,5-a]pyridines et imidazo[1,2-a]pyrazines substituées et leur utilisation
EP3253758B1 (fr) 2015-02-05 2019-04-03 Bayer Pharma Aktiengesellschaft Dérivés substitués-n de carboxamide 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazine-3- en tant que stimulateurs de la guanylatcyclase soluble (gcs) pour le traitement de maladies cardiovasculaires
US10214526B2 (en) 2015-02-05 2019-02-26 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof
WO2018184976A1 (fr) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-carboxamides substitués et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068378B1 (fr) * 1981-06-26 1986-03-05 Schering Corporation Imidazo(1,2-a)pyridines et pyrazines, procédés pour leur préparation et composés pharmaceutiques les contenant
US4468400A (en) * 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
DE3446778A1 (de) * 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
EP0228006A1 (fr) * 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Composés d'imidazopyridine et procédés pour leur préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8903833A1 *

Also Published As

Publication number Publication date
AU2620388A (en) 1989-05-23
HUT51138A (en) 1990-04-28
KR890701587A (ko) 1989-12-21
JPH02501929A (ja) 1990-06-28
DK322189D0 (da) 1989-06-28
DK322189A (da) 1989-06-28
HU203663B (en) 1991-09-30
SE8704248D0 (sv) 1987-10-30
IL88205A0 (en) 1989-06-30
WO1989003833A1 (fr) 1989-05-05

Similar Documents

Publication Publication Date Title
EP0339071A1 (fr) IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE
US6596726B1 (en) Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100392872B1 (ko) 표피성장인자수용체군의티로신키나제를억제할수있는삼환식화합물
EP0790997B1 (fr) 6-ARYLE PYRIDO[2,3-d]PYRIMIDINES ET NAPHTYRIDINES DESTINEES A L'INHIBITION DE LA PROLIFERATION CELLULAIRE INDUITE PAR PROTEINE TYROSINE KINASE
US6720334B2 (en) Urea substituted imidazopyridines
KR100284473B1 (ko) 약제학적 활성을 갖는 비사이클릭-헤테로사이클릭 아민
KR0162654B1 (ko) N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US4725601A (en) Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
CZ1598A3 (cs) Pyrrolopyrimidiny a způsoby jejich přípravy
JP2005538992A (ja) キナーゼ阻害剤
AU2002315006A1 (en) Urea substituted imidazopyridines
US20060035899A1 (en) Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
AU2006264801B2 (en) Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
Su et al. Synthesis and biological activities of 5-deaza analogs of aminopterin and folic acid
US6579884B1 (en) Compounds
BR112020012218A2 (pt) composto de fórmula geral e composição
US4897395A (en) Treatment with dialkoxy pyridopyrimidines
US5354773A (en) Use of bafilomycine and derivatives to treat bone diseases
KR20040111324A (ko) 트리사이클릭 파이라졸로트리아졸로피리미딘 링 구조를지닌 약제학적 활성화합물 및 사용 방법
NZ230098A (en) Compositions containing substituted 2,3-dihydroimidazo-(2,1-a) isoquinolines
WO1989003830A1 (fr) 2-pyridinylmethyle (sulfinyle ou thio)benzimidazoles permettant le traitement de maladies relatives aux pertes osseuses
US5081253A (en) Imidazo(4,5-c)pyridines as antiosteoporotic agents
PT96069A (pt) Processo para a preparacao de compostos imidazo{1,2-a}piridinilalquilo uteis para o tratamento de danos neurotoxicos
AU641445C (en) Bafilomycine macrolides for treatment of bone affecting diseases
US6194574B1 (en) Pyrido[2,3-b]indolizine derivatives and aza analogues thereof: CRF1 specific ligands

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920501